甘李药业股份有限公司2025年第一季度报告

Core Viewpoint - The company reported a significant increase in revenue for the first quarter of 2025, driven by strong domestic sales of insulin products and growth in international markets [5]. Financial Data - The total revenue for the first quarter of 2025 was 985 million yuan, representing an increase of 425 million yuan or 75.76% year-on-year [5]. - Domestic sales revenue reached 889 million yuan, up 395 million yuan or 80.07% compared to the same period last year [5]. - International sales revenue was 95 million yuan, reflecting a growth of 45.21% year-on-year [6]. Revenue Breakdown - Domestic insulin product sales contributed significantly to revenue growth, with sales reaching 864 million yuan, a year-on-year increase of 80.93% [5]. - The sales of long-acting insulin products amounted to 543 million yuan, up 80.97%, while rapid-acting and premixed insulin products generated 321 million yuan, increasing by 80.86% [5]. - The revenue growth was supported by both volume and price increases, with volume contributing 238 million yuan and price contributing 148 million yuan to the revenue [5][6]. Shareholder Information - There were no changes in the top ten shareholders or significant shareholders participating in the securities lending business during the reporting period [7]. Audit Information - The financial statements for the first quarter of 2025 were not audited [2][8].